ANXA9
Annexin A9
Also known as: ANX31, ANXA9_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O76027
- Gene
- ANXA9
- Ensembl
- ENSG00000143412
- Chromosome
- 1
- Canonical length
- 345 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nuclear speckles,Cytosol
- Quaternary structure
- Homodimer
OverviewNCBI Gene
The annexins are a family of calcium-dependent phospholipid-binding proteins. Members of the annexin family contain 4 internal repeat domains, each of which includes a type II calcium-binding site. The calcium-binding sites are required for annexins to aggregate and cooperatively bind anionic phospholipids and extracellular matrix proteins. This gene encodes a divergent member of the annexin protein family in which all four homologous type II calcium-binding sites in the conserved tetrad core contain amino acid substitutions that ablate their function. However, structural analysis suggests that the conserved putative ion channel formed by the tetrad core is intact. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
345 residues, UniProt reviewed canonical sequence.
>O76027|ANXA9
1 MSVTGGKMAP SLTQEILSHL GLASKTAAWG TLGTLRTFLN FSVDKDAQRL LRAITGQGVD
61 RSAIVDVLTN RSREQRQLIS RNFQERTQQD LMKSLQAALS GNLERIVMAL LQPTAQFDAQ
121 ELRTALKASD SAVDVAIEIL ATRTPPQLQE CLAVYKHNFQ VEAVDDITSE TSGILQDLLL
181 ALAKGGRDSY SGIIDYNLAE QDVQALQRAE GPSREETWVP VFTQRNPEHL IRVFDQYQRS
241 TGQELEEAVQ NRFHGDAQVA LLGLASVIKN TPLYFADKLH QALQETEPNY QVLIRILISR
301 CETDLLSIRA EFRKKFGKSL YSSLQDAVKG DCQSALLALC RAEDMLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ANXA9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.28
- Highest tissue expression
- 34 nTPM
Expression across tissuesHPA
Tissue
- pancreas: 34 nTPM
- skin: 31 nTPM
- liver: 28 nTPM
- esophagus: 25 nTPM
- thyroid gland: 23 nTPM
- tonsil: 22 nTPM
Single-cell type
- esophageal apical cells: 393 nCPM
- cholangiocytes: 76 nCPM
- pancreatic duct cells: 66 nCPM
- epididymal efferent duct absorptive cells: 36 nCPM
- prostatic club cells: 29 nCPM
- hepatocytes: 17 nCPM
Immune cell
- myeloid DC: 1.6 nTPM
- classical monocyte: 1.2 nTPM
- neutrophil: 1 nTPM
- eosinophil: 0.7 nTPM
- intermediate monocyte: 0.7 nTPM
- total PBMC: 0.4 nTPM
Brain region
- white matter: 31 nTPM
- medulla oblongata: 26 nTPM
- basal ganglia: 21 nTPM
- midbrain: 21 nTPM
- cerebellum: 20 nTPM
- pons: 19 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.43
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.34
- DepMap mean gene effect
- -0.14
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- acetylcholine receptor activity
- calcium ion binding
- calcium-dependent phospholipid binding
- phosphatidylserine binding
- phospholipid binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ANXA9 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ANXA9 as an antibody target. Whether an autoantibody or antibody against ANXA9 could matter depends on whether native ANXA9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ANXA9 is annotated at the cell surface, where native ANXA9 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label ANXA9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...